EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Halozyme Therapeutics Inc (HALO) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Halozyme Therapeutics Inc $127, price $112, upside +12.6%, quality 79 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN US40637H1095

HT Halozyme Therapeutics Inc logo Some data Sep 24, 2026

Halozyme Therapeutics Inc

HALO · US

Undervalued, solidQuality growthFair Value upside is positive and quality is strong.

✓Fair value $126.64 · Undervalued (+13%)
✓Quality 79/100
!Mixed Growth (revenue 5y +39.2 %/yr)
✓Highly profitable · 23.1% net margin (TTM)
!High debt · generates free cash flow
!Mixed vs. peers (7/12)
✓Wide moat 91/100
!Insider activity 46/100
!Evidence only medium, so the estimate is less certain
Watch Halozyme Therapeutics Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$115.13 $30.28 Fair Value $126.64 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $30.28 – $115.13 · fair‑value band $55.11 – $171.65 · the $112.44 price screens below the $126.64 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Halozyme Therapeutics in your weekly email

Every Wednesday you see whether Halozyme Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.

Show more

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Stock analysis

Halozyme Therapeutics Inc (HALO) currently trades at $112.44, while our model-based Fair Value estimate is $126.64, implying the stock looks roughly 11.2% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $124.12 per share, and 7 of the 24 models we run sit above the $112.44 price.

Bear case: the Multiples group reads lowest at $41.21, and 17 of the 24 models stay below the price. Evidence for this calculation is medium.

Scenario range: $55.11 (bear) to $171.65 (bull), the price of $112.44 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 79/100 (high quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Halozyme Therapeutics Inc reported revenue of $1.4B in FY2025 versus $443M in FY2021, a compound +33.2%/yr. Reported net income was $317M in FY2025, compounding −5.8%/yr from FY2021.

Key figures

Market cap $13.9B · P/E ratio 39.5 · P/S ratio 8.95 · EPS (TTM) $2.85 · Net margin 22.7% · Return on equity 99.4% · Return on assets (EBIT) 23.6% · Operating margin 49.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 2% below its 52-week high and 82% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 13%, HALO screens cheaper than that median.

Fair Value models

Bear $55.11 Fair Value $126.64 Bull $171.65
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($2.08 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV $34.13 $42.20 $49.15 74
FCF DCF $71.48 $119.20 $267.97 72
Growth DCF $66.10 $141.12 $261.97 72
All 24 models by family
DCF Models
FCF DCF $71.48 $119.20 $267.97 72
Owner Earnings $34.74 $97.58 $224.66 66
5Y Revenue Exit $27.90 $52.37 $102.89 66
5Y EBITDA Exit $67.45 $132.32 $259.51 68
5Y P/E Exit $40.89 $101.20 $181.50 65
10Y Revenue Exit $40.65 $90.11 $115.60 64
10Y EBITDA Exit $69.93 $173.32 $352.61 61
10Y P/E Exit $50.98 $117.44 $222.29 58
Earnings-Based
Graham-Dodd $18.17 $126.69 $177.80 61
Lynch FV $65.45 $93.51 $121.56 59
PEG = 1.0 $65.45 $93.51 $121.56 55
EPV $34.13 $42.20 $49.15 74
Multiples
P/E Multiple $44.08 $58.78 $73.47 63
P/S Multiple $30.91 $41.21 $51.51 58
P/B Multiple $1.39 $1.85 $2.31 55
EV/EBIT $70.81 $100.06 $129.31 65
EV/EBITDA $63.12 $89.80 $116.49 67
EV/Revenue $7.79 $18.39 $28.98 50
Asset-Based
NCAV (Graham) $0.2100 $0.2800 $0.4100 54
Growth DCF
Growth DCF $66.10 $141.12 $261.97 72
Rev-Margin DCF $32.06 $62.47 $126.73 66
Economic Profit
Residual Income $2.44 $4.25 $111.30 56
ROIC Compounder $50.50 $86.77 $132.01 67
Growth Earnings
Growth-Adj P/E $86.89 $124.12 $161.36 65

Open the full fair value analysis →

Notify me when HALO reaches fair value

Put HALO on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 79/100

Of which business quality 74 · Market factors (momentum, volatility) 83

Profitability 76
Margins and returns on capital today
Quality Growth 46
Are margins and returns improving?
Cashflow 100
Earnings quality: real cash, not paper profit
Fin. Strength 44
Balance sheet, leverage, solvency risk
Investment 82
Disciplined investing over empire-building
Low Volatility 63
Calm price path (market factor)
Momentum 93
Price trend over the last 3–12 months (market factor)
52W Momentum 88
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 92/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+37.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.2%
Start year 2020 (pandemic). Over 10 years: +26.3% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+57.8%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+22.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+22.4%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.54% → 58%

Growth Forecast

Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+12.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+13.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +9.8% a year for the price and +11.1% for the forecasts.
Forecast 2026 (sales)+26.9%
Forecast 2027 (sales)+12.8%
Projected 2028 (sales)+11.4%
Projected 2029 (sales)+10.1%
Projected 2030 (sales)+8.7%

Watch HALO, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Halozyme Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks

Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 79 · Top 25%
Fair Value upside +13% · Top 25%
Profitability
Return on equity (TTM) 99% · Top 25%
Return on assets 22% · Top 25%
Net margin (TTM) 23% · Top 25%
Operating margin (TTM) 49% · Top 25%
Growth and dividend
Revenue growth 42% · Top 25%
Balance sheet
Debt / equity 43.89× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 39.5× · Pricier than median
P/S (TTM) 9.24× · Pricier than median
P/FCF 21.6× · Priciest 25%
EV/EBITDA 16.7× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)50 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)100 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $514.99 $566.49 +10%
Regeneron Pharmaceuticals, Inc REGN $803.90 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.24 A$197.16 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Halozyme Therapeutics Inc · Fair Value
$126.64 +11%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Halozyme Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/HALO

Frequently asked questions

Is Halozyme Therapeutics Inc (HALO) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $126.64 versus a price of $112.44, about +13% upside (undervalued).
What is the fair value of HALO?
Our model-based fair value for Halozyme Therapeutics Inc is $126.64 (as of Sep 24, 2026), built from audited fundamentals. The current price: $112.44.
What is the quality score of HALO?
Halozyme Therapeutics Inc has a Quality Score of 79/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Halozyme Therapeutics Inc (HALO)?
Our model-based price target is the fair value of $126.64 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $55.11, optimistic scenario $171.65. It is a calculation from audited fundamentals, not an analyst target.
What is the Halozyme Therapeutics Inc stock forecast for 2026?
Our models put fair value at $126.64, about +13% upside versus a price of $112.44 (undervalued). Cautious scenario $55.11, optimistic scenario $171.65. The calculation is refreshed regularly with new filings.
What is the revenue of Halozyme Therapeutics Inc (HALO)?
Halozyme Therapeutics Inc reported trailing-twelve-month revenue of about $1.5B (latest available figure, as of Sep 24, 2026).
What growth is priced into Halozyme Therapeutics Inc (HALO)?
For today's price to be fair in a discounted-cash-flow model, Halozyme Therapeutics Inc would have to grow free cash flow by +12.5 % per year for five years (discount rate 9.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +39.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of HALO use?
Our models discount Halozyme Therapeutics Inc at 9.3 %: a base by market capitalisation (mid), damped by beta 0.84, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Halozyme Therapeutics Inc that is +12.5 % per year a year over ten years, using the same discount rate (9.3 %) and the same formula as our fair value.
How much growth has Halozyme Therapeutics Inc (HALO) delivered so far?
Over the past 5 years revenue at Halozyme Therapeutics Inc grew +39.2 % a year. The price currently implies +12.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Halozyme Therapeutics Inc (HALO) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Halozyme Therapeutics Inc (+12.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Halozyme Therapeutics Inc (HALO)?
The free-cash-flow yield on the price is 4.63 %: that much free cash flow Halozyme Therapeutics Inc produces per unit of market value. When it exceeds the discount rate of our models (9.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Halozyme Therapeutics Inc (HALO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Halozyme Therapeutics Inc it is $126.64 per share (as of Sep 24, 2026), against a price of $112.44. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Halozyme Therapeutics Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, HALO trades below its calculated fair value: price $112.44, fair value $126.64, a gap of about +13% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HALO?
No. The price is what the market pays today ($112.44); the fair value is what the company's own numbers justify ($126.64). For Halozyme Therapeutics Inc the two are $14.20 per share apart. That gap is exactly why we show both numbers side by side.
How much is Halozyme Therapeutics Inc worth?
The market values Halozyme Therapeutics Inc at about $13.9B (market capitalisation, as of Sep 24, 2026). Per share that is $112.44; our models calculate a fair value of $126.64 per share.
What do the bullish and bearish scenarios say about HALO?
Our models span a range for Halozyme Therapeutics Inc: cautious scenario $55.11, base $126.64, optimistic $171.65 per share (as of Sep 24, 2026, price $112.44). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HALO?
Halozyme Therapeutics Inc trades at a price-to-earnings ratio of 39.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $126.64 is built from several models across several years. Other multiples: P/S 9.2, EV/EBITDA 16.7.
How solid is the balance sheet of Halozyme Therapeutics Inc (HALO)?
Balance-sheet figures for Halozyme Therapeutics Inc (as of Sep 24, 2026): return on equity 99.4%. They feed the Quality Score of 79/100, which measures business quality independently of the share price.
How far is HALO from its 52-week high?
Halozyme Therapeutics Inc trades at $112.44, about 2% below its 52-week high of $115.13 and 82% above the low of $61.63 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $126.64 is for.
Which stocks are comparable to Halozyme Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Halozyme Therapeutics Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $112.44, calculated fair value $126.64 (+13%), Quality Score 79/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HALO calculated?
We run Halozyme Therapeutics Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $126.64, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Halozyme Therapeutics Inc currently trades 13 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Halozyme Therapeutics Inc (HALO)?
The closing price on Sep 23, 2026 was $112.44. Our model-based fair value is $126.64, about +13% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Halozyme Therapeutics Inc right now?
The model range is unusually wide ($55.11 to $171.65). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Halozyme Therapeutics Inc

How large is the market capitalisation of Halozyme Therapeutics Inc (HALO)?
The market capitalisation of Halozyme Therapeutics Inc is $13.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Halozyme Therapeutics Inc (HALO)?
The price-to-sales ratio of Halozyme Therapeutics Inc is 8.95 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Halozyme Therapeutics Inc (HALO)?
Earnings per share at Halozyme Therapeutics Inc are $2.85 (price ÷ EPS = P/E 39.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Halozyme Therapeutics Inc (HALO)?
The net margin of Halozyme Therapeutics Inc is 22.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Halozyme Therapeutics Inc (HALO)?
The return on equity (ROE) of Halozyme Therapeutics Inc is 99.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Halozyme Therapeutics Inc (HALO)?
On an EBIT basis the return on assets of Halozyme Therapeutics Inc is 23.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Halozyme Therapeutics Inc (HALO)?
The operating margin of Halozyme Therapeutics Inc is 49.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Halozyme Therapeutics Inc (HALO)?
Revenue at Halozyme Therapeutics Inc is growing +42.2% versus a year earlier (3y avg +28.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Halozyme Therapeutics Inc (HALO)?
Earnings per share at Halozyme Therapeutics Inc are growing +31.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Halozyme Therapeutics Inc (HALO) carry?
The net debt of Halozyme Therapeutics Inc is $2.0B (fiscal year 2025, ≈ 3.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Halozyme Therapeutics Inc in the live analysis

One click puts Halozyme Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.